126
Participants
Start Date
October 4, 2016
Primary Completion Date
July 30, 2018
Study Completion Date
July 30, 2018
Bevacizumab + FOLFIRI-3
Bevacizumab 5 mg/kg will be administered at day 1 every 2 weeks. Initially, it will be administered as a 90-min infusion. If the first infusion is well tolerated, the second will be delivered as a 60-min infusion, and if the 60-min infusion is well tolerated, all subsequent infusions will be given over 30 minutes. FOLFIRI-3 regimen consists of irinotecan 100 mg/m2 over 1 hour at day 1, leucovorin 400 mg/m2 at day 1 followed by a 46 hour 5-FU continuous infusion (2000 mg/m2) and irinotecan 100 mg/m2 over 1 hour on day 3 will administer. Induction treatment was administrated every 2 weeks until disease progression, unacceptable toxicities, surgical intervention, or withdrawal of consent.
Shafa Hospital, Ahvāz
Shahid Beheshti Hospital, Hamadan
Saba Clinic, Isfahan
Sheikh Mofid, Isfahan
Payandeh Clinic, Kermanshah
Shazad Clinic, Kermanshah
Imam Reza Hospital, Mashhad
Qaem Hospital, Mashhad
Rasool Hospital, Rasht
Razi Hospital, Rasht
Namazi Hospital, Shiraz
Firoozgar Hospital, Tehran
Imam Khomeini Hospital, Tehran
Imam Reza Hospital (501 Artesh), Tehran
Masih Daneshvari Hospital, Tehran
Masoud Internal Clinic, Tehran
Safa najafi clinic, Tehran
Shariati Hospital, Tehran
Sina Hospital, Tehran
Taleqani Hospital, Tehran
Mortazavizadeh Clinic, Yazd
Seyedshohada Hospital, Yazd
Lead Sponsor
AryoGen Pharmed Co.
INDUSTRY